Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Johnson & Johnson Interventional Systems

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson Interventional Systems: Investigational device exemption application for JJIS heparin-coated coronary stent is expected to be filed with FDA before the end of 1995. The stent, which has active heparin "covalently bonded" to its surface, has been implanted in over 200 patients in Europe, JJIS President Marvin Woodall told analysts at the Piper Jaffray cardiology conference in New York City on Feb. 7. There have been no incidences of sub-acute thrombosis in the study, and six-month angiographic data from the first 50 patients in the trial shows a restenosis rate of 13%, Woodall noted. JJIS is the only company marketing a stent in the U.S. as an alternative treatment to balloon angioplasty. Palmaz-Schatz was approved in August for use in selected patients with coronary artery disease who are eligible for angioplasty ("The Gray Sheet" Aug. 8, 1994, p. 6)...
UsernamePublicRestriction

Register

MT003478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel